Doctor Samuel Dagogo-Jack
Memphis (United States of America)
Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.
Event: ESC Congress 2018
Topic: Cardiovascular Disease in Special Populations
Session: Five things cardiologists should know about diabetes
Questions & Answers.
Event: ESC Congress 2018
Topic: Cardiovascular Disease in Special Populations
Session: Five things cardiologists should know about diabetes
Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.
Event: ESC Congress 2018
Topic: Cardiovascular Disease in Special Populations
Session: Five things cardiologists should know about diabetes
ESC 365 is supported by
